Mechanisms of action of troglitazone in the prevention of high glucose- induced migration and proliferation of cultured coronary smooth muscle cells

Circulation Research

Volumn 81, Issue 6, 1997, Pages 953-962

  Yasunari, Kenichi ^a   Kano, Masakazu ^b   Kano, Hiroaki ^b   Yokokawa, Koji ^b   Minami, Mieko ^b   Yoshikawa, Junichi ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Antioxidant; Glucose; Phospholipase D; Protein kinase C; Vascular smooth muscle

Indexed keywords

PHOSPHOLIPASE D; PROTEIN KINASE C; TROGLITAZONE;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; HYPERGLYCEMIA; INSULIN RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RABBIT; RISK FACTOR; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0343683281     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.81.6.953     Document Type: Article

References (46)

1. Stearns S, Schlesingh MJ, Rudy A. Incidence and clinical significance of coronary artery disease in diabetes mellitus. Arch Intern Med. 1947;80:463-474.
2. Stein B, Weintraub WS, Gebhart SSP, Cohen-Bernstein CL, Grosswald R, Liberman HA, Douglas JS Jr, Morris DC, King SB III. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995;91:979-989.
3. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500.
4. Williamson JR, Chang K, Frongos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, Enden MVD, Kilo C, Tilton RG. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 1993;42:801-813.
5. Nagasawa Y, Kaku K, Nakamura K, Kaneko T, The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vivo. Biochem Pharmacol. 1995;50:1109-1101.
6. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res. 1992;70:593-599.
7. Després J-P, Lamarche B, Mauri ge P, Cantin B, Dagenais GR, Moorjani S, Lupien P-J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
8. Young MH, Jeng C-Y, Sheu WH-H, Shieh S-M, Fuh MM-T, Chen Y-DI, Reaven GM. Insulin resistance, glucose intolerance, hyperinsulinemia and dyslipidemia in patients with angiographically demonstrated coronary artery disease. Am J Cardiol. 1993;72:458-460.
9. Yasunari K, Kohno M, Murakawa K, Yokokawa K, Horio T, Takeda T, Interaction between a phorbol ester and dopamine DA1 receptors on vascular smooth muscle. Am J Physiol. 1993;264:F24-F30.
10. Yasunari K, Kohno M, Yokokawa K, Horio T, Takeda T. Dopamine DA1 receptors on vascular smooth muscle cells are regulated by glucocorticoid and sodium chloride. Am J Physiol. 1994;267:R628-R634.
11. Horio T, Kohno M, Kano H, Ikeda M, Yasunari K, Yokokawa K, Minami M, Takeda T. Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. Circ Res, 1995;77:660-664.
12. Yasunari K, Kohno M, Balmforth AJ, Murakawa K, Yokokawa K, Kurihara N, Takeda T. Glucocorticoid and dopamine-I receptors on vascular smooth muscle. Hypertension. 1989;13:575-581.
13. Kano H, Kohno M, Yasunari K, Yokokawa K, Horio T, Ikeda M, Minami M, Hanehira T, Takeda T, Yoshikawa J. Adrenomedullin as a novel antiproliferative factor of vascular smooth muscle cells. J Hypertens. 1996;14:209-213.
14. Yasunari K, Kohno M, Kano H, Yokokawa K, Horio T, Yoshikawa J. Aldose reductase inhibitor prevents hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucose. Arterioscler Thromb Vasc Biol. 1995;15:2207-2212.
15. Williamson DH, Lund P, Krebs HA. The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver. Biochem J. 1967;103:514-527.
16. Yasunari K, Kohno M, Kano H, Yokokawa K, Horio T, Yoshikawa J. Possible involvement of phospholipase D and protein kinasc C in elevated glucose concentration induced vascular growth. Hypertension. 1996;28:159-168.
17. Yasunari K, Kohno M, Murakawa K, Yokokawa K, Horio T, Takeda T. Phorbol ester and atrial natriuretic peptide receptor response on vascular smooth muscle. Hypertension. 1992;19:314-319.
18. Wallenstein SW, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res. 1980;47:1-9.
19. Shibata H, Nii S, Kobayashi M, Izumi T, Maeda E, Sasahara K, Yamaguchi K, Morita A, Nishimaki A. Phase-1 study of a new hypoglycemic agent CS-045 in healthy volunteers. Rinsho Iyaku. 1993;17:1503-1518. English abstract.
20. Law RE, Meehan WP, Xi X-P, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897-1905.
21. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-412.
22. Suudaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science. 1995;270:296-299.
23. Exon JH. Signaling through phosphatidylcholine break down. J Biol Chem. 1990;265:1-4.
24. Bornfeldt KE, Raines EW, Nakauo T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathway that are distinct migration from proliferation. J Clin Invest. 1994;93:1266-1274.
25. Vinson JA, Starez ME, Bose P, Kassan HM, Basalyga BS. In vitro and in vivo reduction of erythrocyte sorbitol by ascorbic acid. Diabetes. 1989;38:1036-1041.
26. Lee TS, Sallsman KA, Ohashi H, King GL. Activation of protein kinasc C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A. 1989;86:5141-5145.
27. Ohara Y, Peterson TE, Zheng B, Kuo JF, Harrison DG. Lysophosphatidyl choline increases vascular superoxide anion via protein kinase C activation. Arterioscler Thromb Vasc Biol. 1994;14:1007-1013.
28. Williams B, Schrier RW. Characterization of glucose-induced in situ protein kinase C activity in cultured vascular smooth muscle cells. Diabetes. 1992;41:1464-1472.
29. Nishizuka Y. Protein kinase C and lipid signaling of sustained cellular responses. FASEB J. 1995;9:484-496.
30. Lassegue B, Alexander RW, Clark M, Akers M, Griendling KK. Phosphatidylcholine is a major source of phosphatidic acid and diacylglycerol in angiotensin II-stimulated vascular smooth muscle cells. Biochem J. 1993;292:509-517.
31. Lee M-K, Miles PDG, Khoursheed M, Gao K-M, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 1994;43:1435-1439.
32. Nolan LL, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-1193.
33. 2 is a ligand for the adipocyte determination factor PPAR γ. Cell 1995;83:803-812.
34. Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn R, Mosthaf L, Häring H, Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes. 1994;43:447-453.
35. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol. 1993;265:R726-R732.
36. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 1992;15:318-368.
37. Winegrad AI. Banting Lecture 1986: does a common mechanism induce the diverse complications of diabetes? Diabetes. 1987;36:396-406.
38. Stout RW. Diabetes and atherosclerosis: the role of insulin. Diabetologia. 1979;16:141-150.
39. Fujiwara R, Nakai T. Effect of glucose, insulin, and insulin-like growth factor-I on glucose transport activity in cultured rat vascular smooth muscle cells. Atherosclerosis. 1996;127:49-57.
40. Muller HK, Kellerer M, Ermel B, Muhlhofer A, Obermaier-Kusser B, Vogt B, Häring HU. Prevention by protein kinase C inhibitors of glucose-induced insulin receptor tyrosine kinase resistance in rat fat cells. Diabetes. 1991;40:1440-1448.
41. McCarty MF. Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension atherogenesis, insulin resistance, and cancer promotion: the 'PKC syndrome.' Med Hypotheses. 1996;46:191-221.
42. Pfeifle B, Ditschuneit H. Two separate receptors for insulin and insulinlike growth factor on arterial smooth muscle cells. Exp Clin Endocrinol 1983;81:280-286.
43. King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest. 1985;75:1028-1036.
44. Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells: comparison of maximal growth promoting activities. Diabetologia. 1991;34:307-313.
45. Cooper DR, Khalakdina A, Watson JE. Chronic effects of glucose on insulin signaling in A-10 vascular smooth muscle cells. Arch Biochem Biophys. 1993;302:490-498.
46. DeFronzo RA. The triumvirate: β-cell, muscle, liver. Diabetes. 1988;37:667-687.